Biogenerics Moving Closer to Commercialization

Share Article

Biogenerics will have a major impact on the worldwide pharmaceutical marketplace according to Arrowhead Publishers' new report Biogenerics: Challenges and Promise (

The traditional line between research-based pharmaceutical companies and the growing generics industry is rapidly fading. More and more companies that straddle that changing boundary are beginning to understand and appreciate the benefits of a mixed portfolio. As generic companies begin moving up the value chain to higher priced products, the pharma giants are increasingly exploring the potential of the fast-growing biogenerics industry.

Biogenerics: Challenges and Promise, a new report from Arrowhead Publishers, takes an insightful look at the burgeoning biogenerics industry.

The report analyzes how the generics industry will be shaped by the global healthcare market and regulatory developments over the next five years.

The international biogenerics market faces a multitude of challenges. Biogenerics: Challenges and Promise will assesses those challenges and analyzes the potential for maximizing the myriad opportunities available in this competitive and dynamic industry. The report also appraises and compares current and emerging biogeneric products and identifies those with the most potential for growth.

Key questions answered in this report:

•Who are the major players in the biogenerics arena and what kind of impact are they making on the industry?

•What obstacles stand in the way of a smooth transition from biopharmaceutical manufacture to biogenerics?

•How has the lack of a clear framework impeded the industry’s progress in producing and distributing biogeneric drugs? And how will these issues be resolved?

•What specific hurdles must biogeneric manufacturers maneuver in order to get their products on the market?

This new Arrowhead report contains:

•Thorough analysis of the drivers of and restraints on the biogenerics market

•Detailed information and analysis concerning groundbreaking biogeneric regulation in the US and Europe.

•Identification of key biopharmaceuticals at risk for biogeneric competition

•In-depth profiles of leading pharmaceutical companies involved in the biogenerics industry

•Analytical discussions which integrate regulatory issues with market activity

and company activity


Sales Department


# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website